BioNTech Partners with Duality Biologics
Tuesday, April 04, 2023
BioNTech and Duality Biologics announced that the companies have entered into exclusive licence and collaboration agreements for two ADC assets to develop, manufacture and commercialise the two assets globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in BioNTech’s oncology portfolio with the aim to further support BioNTech’s mission of developing highly efficacious therapies for cancer patients at every stage of disease.
- BioNTech receives exclusive licences from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers
- This Collaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stage oncology portfolio, expanding the breadth of its immunotherapy toolkit with synergistic potential
Under the terms of the agreements, DualityBio will receive upfront payments for both asset licences totaling $170 million, and additional development, regulatory and commercial milestone payments for both assets, potentially totaling over $1.5 billion. DualityBio will be eligible to receive single-digit to double-digit tiered royalties on net sales for both ADC assets. BioNTech will hold commercial rights globally (excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region), while DualityBio will retain commercial rights for Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. As part of the agreement for DB-1311, DualityBio has the right to exercise a co-development cost and profit/loss sharing option for DB-1311 for the U.S. market, as well as a co-promotion option for the U.S. market.
